| 王 闰,许 勇,王 琦,沈 燕,童 强.吡柔比星膀胱灌注化疗对浅表性膀胱癌术后患者血清恶性肿瘤相关因子和增殖侵袭基因表达的影响[J].,2023,(9):1681-1684 |
| 吡柔比星膀胱灌注化疗对浅表性膀胱癌术后患者血清恶性肿瘤相关因子和增殖侵袭基因表达的影响 |
| Effect of Intravesical Chemotherapy with Pirarubicin on the Expression of Serum Tumor Related Factors and Proliferation Invasion Genes in Patients with Superficial Bladder Cancer after Operation |
| 投稿时间：2022-10-02 修订日期：2022-10-24 |
| DOI：10.13241/j.cnki.pmb.2023.09.016 |
| 中文关键词: 吡柔比星 膀胱灌注化疗 浅表性膀胱癌 恶性肿瘤相关因子 增殖侵袭基因 |
| 英文关键词: Pirarubicin Intravesical chemotherapy Superficial bladder cancer Malignant tumor related factors Proliferation invasion gene |
| 基金项目:上海市自然科学基金项目（17ZR1436432） |
|
| 摘要点击次数: 810 |
| 全文下载次数: 457 |
| 中文摘要: |
| 摘要 目的：探讨浅表性膀胱癌术后患者采用吡柔比星膀胱灌注化疗后，血清增殖侵袭基因表达和恶性肿瘤相关因子的影响。方法：选取中国人民解放军海军第九零五医院2018年3月~2019年4月期间收治的浅表性膀胱癌患者98例，按照随机数字表法分为对照组（经尿道膀胱肿瘤切除术（TURBT）治疗）和研究组（对照组的基础上接受吡柔比星膀胱灌注化疗），各为49例。对比两组疗效、血清恶性肿瘤相关因子、增殖侵袭基因表达、不良反应发生率和复发率。结果：研究组的临床总有效率高于对照组（P<0.05）。化疗后，两组血清血管内皮生长因子（VEGF）、成纤维细胞生长因子（FGF）及基质金属蛋白酶-9（MMP-9）水平均下降，且研究组均低于对照组同期（P<0.05）。化疗后，两组增殖基因三磷酸腺苷结合盒转运子E1（ABCE1）、核转运蛋白α2（KPNA2)、线粒体核糖体蛋白S5（MRPS5），侵袭基因整合素相关激酶（ILK）、核因子-κBp65（NF-κBp65）下降，且研究组低于对照组同期；侵袭基因过氧化物酶体增殖物激活受体γ（PPARγ）升高，且研究组高于对照组同期（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。研究组术后1年、2年、3年复发率均低于对照组（P<0.05）。结论：吡柔比星膀胱灌注化疗用于浅表性膀胱癌术后患者，可有效调节血清恶性肿瘤相关因子水平和增殖侵袭基因表达的影响，降低肿瘤复发率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of pirarubicin intravesical infusion chemotherapy on the expression of serum proliferative invasion genes and tumor related factors in postoperative patients with superficial bladder cancer. Methods: 98 patients with superficial bladder cancer who were admitted to 905 Hospital of the Chinese People's Liberation Army Navy from March 2018 to April 2019 were randomly seleceted, they were divided into control group [treated with transurethral resection of bladder tumor (TURBT)] and study group (treated with intravesical chemotherapy of pirarubicin on the basis of the control group), with 49 cases in each group. The curative effect, serum tumor related factors, expression of proliferation and invasion genes, adverse reaction rate and recurrence rate were compared between the two groups. Results: The total clinical effective rate of the study group was higher than that of the control group (P<0.05). After chemotherapy, the levels of serum vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and matrix metalloproteinase-9 (MMP-9) in the two groups decreased, and the levels in the study group were lower than those in the control group at the same period (P<0.05). After chemotherapy, adenosine triphosphate binding cassette transporter E1 (ABCE1) and nuclear transporter of two groups of proliferating genes α 2 (KPNA2), mitochondrial ribosomal protein S5 (MRPS5), invasion gene integrin related kinase (ILK), nuclear factor-κBp65（NF-κBp65) decreased, and the study group was lower than the control group in the same period; Invasive gene peroxisome proliferator activated receptorγ （PPARγ）. It was higher in the study group than in the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). The recurrence rate in the study group at 1, 2 and 3 years after operation was lower than that in the control group (P<0.05). Conclusion: Pirarubicin intravesical infusion chemotherapy for postoperative patients with superficial bladder cancer can effectively regulate the level of serum tumor related factors and the expression of proliferation and invasion genes, and reduce the recurrence rate of tumor. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
